# Kymera Therapeutics Inc. (KYMR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $117.39, market value $9.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Kymera Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 92.0×**. Each dollar of revenue is priced at 92.0×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 6.4×**. The shares trade at 6.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -2.5%** (5-yr avg -7.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -333.5%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -794.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -19.7%**. Return on equity is negative because earnings are negative.
- **Return on assets: -17.2%**. Each dollar of assets produces -17.2% of profit.

## Growth
- **Revenue growth (1 yr): -16.7%** (3-yr -5.7%/yr, 5-yr 2.9%/yr). Revenue fell 16.7% over the last year, against 2.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -23.8%**. Earnings per share fell 23.8%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 10.47** (quick 10.47). Current assets cover the next year's liabilities 10.47 times.
- **Altman Z-score: 36.68**. A Z-score of 36.68 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Kymera Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (21 analysts). 21 analysts cover Kymera Therapeutics Inc.; the consensus is strong_buy, with an average price target of $134.71 (+15% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 178.2%** (YTD 50.9%, 3-mo 58.4%). The shares are up 178.2% over twelve months including dividends.
- **From 52-week high: -9.7%** (174.9% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 0.86** (volatility 63%). Beta of 0.86 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=KYMR · Page: https://foliofundamentals.com/stocks/kymr

Not investment advice.